WO2008063984A3 - Allosteric modulators of the a1 adenosine receptor - Google Patents

Allosteric modulators of the a1 adenosine receptor Download PDF

Info

Publication number
WO2008063984A3
WO2008063984A3 PCT/US2007/084490 US2007084490W WO2008063984A3 WO 2008063984 A3 WO2008063984 A3 WO 2008063984A3 US 2007084490 W US2007084490 W US 2007084490W WO 2008063984 A3 WO2008063984 A3 WO 2008063984A3
Authority
WO
WIPO (PCT)
Prior art keywords
adenosine receptor
formula
allosteric modulators
compounds
pain
Prior art date
Application number
PCT/US2007/084490
Other languages
French (fr)
Other versions
WO2008063984A2 (en
Inventor
Pier Giovanni Baraldi
Allan R Moorman
Romeo Romagnoli
Original Assignee
King Pharmaceuticals Res & Dev
Pier Giovanni Baraldi
Allan R Moorman
Romeo Romagnoli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US11/938,465 external-priority patent/US7855209B2/en
Priority claimed from US11/938,514 external-priority patent/US7897596B2/en
Priority to EP07864306A priority Critical patent/EP2081575A4/en
Priority to AU2007323888A priority patent/AU2007323888A1/en
Priority to JP2009537305A priority patent/JP2010509402A/en
Priority to KR1020097009765A priority patent/KR20090112627A/en
Application filed by King Pharmaceuticals Res & Dev, Pier Giovanni Baraldi, Allan R Moorman, Romeo Romagnoli filed Critical King Pharmaceuticals Res & Dev
Priority to MX2009004763A priority patent/MX2009004763A/en
Priority to CA002669447A priority patent/CA2669447A1/en
Priority to BRPI0718520-0A priority patent/BRPI0718520A2/en
Publication of WO2008063984A2 publication Critical patent/WO2008063984A2/en
Publication of WO2008063984A3 publication Critical patent/WO2008063984A3/en
Priority to IL198402A priority patent/IL198402A0/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D333/30—Hetero atoms other than halogen
    • C07D333/36—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • C07D491/113—Spiro-condensed systems with two or more oxygen atoms as ring hetero atoms in the oxygen-containing ring

Abstract

The present invention provides compounds of formula (I) wherein R1, R2, R3, R4 and Q have a meaning as defined herein in the specification. The compounds of formula (I) are allosteric modulators of the A1 adenosine receptor and, thus, may be employed for the treatment of conditions mediated by the A1 adenosine receptor. Accordingly, the compounds of formula (I) may be employed for treatment of pain, in particular, chronic pain such as neuropathic pain; cardiac disease or disorder such as cardiac disarrhythmias, e.g., peroxysmal supraventricular tachycardia, angina, myocardial infarction and stroke; neurological disease or injury; sleep disorder; epilepsy; and depression.
PCT/US2007/084490 2006-11-13 2007-11-13 Allosteric modulators of the a1 adenosine receptor WO2008063984A2 (en)

Priority Applications (8)

Application Number Priority Date Filing Date Title
BRPI0718520-0A BRPI0718520A2 (en) 2006-11-13 2007-11-13 COMPOSITION, METHODS FOR ADENOSINE A1 RECEPTOR MODULATION AND FOR THE TREATMENT OF CONDITIONS MEDIATED BY ADENOSINE A1 RECEIVER IN MAMMALS, PHARMACEUTICAL COMPOSITION, AND USES OF A COMPOSITION AND A COMPOUND
CA002669447A CA2669447A1 (en) 2006-11-13 2007-11-13 Allosteric modulators of the a1 adenosine receptor
AU2007323888A AU2007323888A1 (en) 2006-11-13 2007-11-13 Allosteric modulators of the A1 adenosine receptor
JP2009537305A JP2010509402A (en) 2006-11-13 2007-11-13 Allosteric modulator of A1 adenosine receptor
KR1020097009765A KR20090112627A (en) 2006-11-13 2007-11-13 Adenosine Modulators of the A1 Adenosine Receptor
EP07864306A EP2081575A4 (en) 2006-11-13 2007-11-13 Allosteric modulators of the a1 adenosine receptor
MX2009004763A MX2009004763A (en) 2006-11-13 2007-11-13 Allosteric modulators of the a1 adenosine receptor.
IL198402A IL198402A0 (en) 2006-11-13 2009-04-26 Allosteric modulators of the a1 adenosine receptor

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US85850506P 2006-11-13 2006-11-13
US60/858,505 2006-11-13
US11/938,514 2007-11-12
US11/938,465 2007-11-12
US11/938,465 US7855209B2 (en) 2006-11-13 2007-11-12 Allosteric modulators of the A1 adenosine receptor
US11/938,514 US7897596B2 (en) 2006-11-13 2007-11-12 Allosteric modulators of the A1 adenosine receptor

Publications (2)

Publication Number Publication Date
WO2008063984A2 WO2008063984A2 (en) 2008-05-29
WO2008063984A3 true WO2008063984A3 (en) 2008-08-14

Family

ID=39430473

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2007/084490 WO2008063984A2 (en) 2006-11-13 2007-11-13 Allosteric modulators of the a1 adenosine receptor

Country Status (9)

Country Link
EP (1) EP2081575A4 (en)
JP (1) JP2010509402A (en)
KR (1) KR20090112627A (en)
AU (1) AU2007323888A1 (en)
BR (1) BRPI0718520A2 (en)
CA (1) CA2669447A1 (en)
IL (1) IL198402A0 (en)
MX (1) MX2009004763A (en)
WO (1) WO2008063984A2 (en)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103739588B (en) * 2014-01-04 2015-07-01 新发药业有限公司 Simple synthesis method of 2-aminothiophene derivative
US10434099B2 (en) 2016-09-22 2019-10-08 The National Institute for Biotechnology in the Negev Ltd. Methods for treating central nervous system disorders using VDAC inhibitors
US10787423B2 (en) 2015-09-14 2020-09-29 The National Institute For Biotechnolgy In The Negev Ltd. Piperazine and piperidine derivatives, their synthesis and use thereof in inhibiting VDAC oligomerization, apoptosis and mitochondria dysfunction
EP3736272A1 (en) * 2015-09-14 2020-11-11 The National Institute for Biotechnology in the Negev Ltd. Novel piperazine and piperidine derivatives, their synthesis and use thereof in inhibiting vdac oligomerization, apoptosis and mitochondria dysfunction
US10961249B2 (en) 2017-03-21 2021-03-30 Temple University-Of The Commonwealth System Of Higher Education Modulators of the sigma-2 receptor and their method of use
US11220505B2 (en) * 2017-03-21 2022-01-11 Temple University-Of The Commonwealth System Of Higher Education 5-hydroxytryptamine receptor 7 modulators and their use as therapeutic agents

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5332732A (en) * 1992-09-11 1994-07-26 Mcneilab, Inc. Thiophene and pyridine antipsychotic agents
US5750728A (en) * 1992-10-29 1998-05-12 Clariant Gmbh Process for the preparation of aromatic bromomethyl compounds
US5939432A (en) * 1997-10-29 1999-08-17 Medco Research, Inc. Thiophenes useful for modulating the adenosine receptor

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5332732A (en) * 1992-09-11 1994-07-26 Mcneilab, Inc. Thiophene and pyridine antipsychotic agents
US5750728A (en) * 1992-10-29 1998-05-12 Clariant Gmbh Process for the preparation of aromatic bromomethyl compounds
US5939432A (en) * 1997-10-29 1999-08-17 Medco Research, Inc. Thiophenes useful for modulating the adenosine receptor

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
GUTIERREZ-DE-TERAN ET AL.: "Novel approaches for modeling of the A1 adenosine receptor and its agonist binding site", PROTEINS, vol. 54, no. 4, March 2004 (2004-03-01), pages 705 - 715, XP008109385 *

Also Published As

Publication number Publication date
EP2081575A4 (en) 2010-01-06
AU2007323888A1 (en) 2008-05-29
JP2010509402A (en) 2010-03-25
EP2081575A2 (en) 2009-07-29
KR20090112627A (en) 2009-10-28
MX2009004763A (en) 2009-05-21
WO2008063984A2 (en) 2008-05-29
CA2669447A1 (en) 2008-05-29
BRPI0718520A2 (en) 2013-11-19
IL198402A0 (en) 2010-02-17

Similar Documents

Publication Publication Date Title
WO2008063984A3 (en) Allosteric modulators of the a1 adenosine receptor
WO2008097428A3 (en) Compounds and compositions as modulators of gpr119 activity
WO2008001195A3 (en) Novel processes for the preparation of dpp iv inhibitors
WO2009043889A3 (en) Oxadiazole derivatives
WO2010045258A3 (en) Spirocyclic gpr40 modulators
WO2009068033A3 (en) Lna antagonists targeting the androgen receptor
WO2009111700A3 (en) Oxadiazoanthracene compounds for the treatment of diabetes
WO2008070111A3 (en) Processes for preparing (r)-8-chloro-1-methyl-2,3,4,5-tetrahydro-1h-3-benzazepine and intermediates thereof
PT1858877E (en) 1,3 substituted diaryl ureas as modulators of kinase activity
UA103198C2 (en) Squaramide derivatives as cxcr2 antagonists
NZ592544A (en) Isonicotinamide orexin receptor antagonists
EA200870470A1 (en) INHIBITORS 11-BETA HYDROXYSTEROID DEHYDROGENASE 1
WO2007059257A3 (en) N4-phenyl-quinaz0line-4 -amine derivatives and related compounds as erbb type i receptor tyrosine kinase inhibitors for the treatment of hyperproliferative diseases
IL232619A0 (en) Compositions suitable for treatment of spinal disease, disorder or condition
WO2010014836A3 (en) Tgr5 modulators and methods of use thereof
WO2009117421A3 (en) Heterocyclic modulators of gpr119 for treatment of disease
WO2008059370A3 (en) Substituted bicyclocarboxyamide compounds
IL209896A0 (en) Compounds for treating symptoms associated with parkinson's disease
WO2006131322A3 (en) Use op brivaracetam for the treatment of diseases characterized by progressive myoclonic epilepsy
WO2007095586A3 (en) Neuronal pain pathway modulators
WO2008050199A8 (en) Substituted phenylmethyl bicyclocarboxyamide compounds
WO2007072201A3 (en) 3-aminocyclopentanecarboxamides as modulators of chemokine receptors
WO2006076370A3 (en) Substituted cyclopentanes or cyclopentanones for the treatment of ocular hypertensive conditions
WO2007136668A3 (en) N-benzoyl-and n-benzylpyrrolidin-3-ylamines as histamine-3 antagonists
WO2008045371A3 (en) N-substituted-azacyclylamines as histamine-3 antagonists

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 200780042111.7

Country of ref document: CN

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 07864306

Country of ref document: EP

Kind code of ref document: A2

WWE Wipo information: entry into national phase

Ref document number: 2007323888

Country of ref document: AU

Ref document number: 576382

Country of ref document: NZ

WWE Wipo information: entry into national phase

Ref document number: 198402

Country of ref document: IL

WWE Wipo information: entry into national phase

Ref document number: 819/MUMNP/2009

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: MX/A/2009/004763

Country of ref document: MX

WWE Wipo information: entry into national phase

Ref document number: 2669447

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2007864306

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 2009537305

Country of ref document: JP

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 1020097009765

Country of ref document: KR

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 2007323888

Country of ref document: AU

Date of ref document: 20071113

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: PI0718520

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20090507